Anti-inflammatory Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

The global Anti-inflammatory Drugs Market is projected to be worth $1.5 billion.

Anti-inflammatory medications are a type of painkiller that is used to treat a variety of inflammatory conditions. These medications are used to treat pain, inflammation, and fever. These medications are available in pills, capsules, creams, liquids, injections, sprays, and suppositories all over the world, both on prescription and off. Furthermore, the rising prevalence of acute and chronic disorders is likely to drive market expansion. According to a November 2019 article published by the National Kidney Foundation Inc., the prevalence of gout in the United States has doubled since the 1990s, and it is now estimated that 3.9 percent of adults in the United States, or 8.3 million adults, have gout, with 6.1 million men and 2.2 million women.

The worldwide Anti-inflammatory Drugs Market is predicted to rise due to ongoing anti-inflammatory drug research and development.

Over the projection period, the market is expected to increase due to ongoing research and development, as well as approvals and launches of anti-inflammatory medications. For example, the U.S. Food and Drug Administration (US FDA) and the European Medicines Agency (EMA) both gave good replies to InDex Pharmaceuticals Holding AB's phase III trial of TLR9 agonist cobitolimod in April 2020. This drug could be a new treatment option for those who have active ulcerative colitis, a chronic inflammatory bowel disease.

Over the projection period, however, failure of therapeutic findings in clinical trials is expected to stymie market expansion. For example, F. Hoffmann-La Roche AG, a worldwide healthcare company, announced in July 2020 that its COVACTA study of the anti-inflammatory medicine Actemra (tocilizumab) had failed to fulfil its primary aim of improvement. The medicine was supposed to help patients who were hospitalised with severe COVID-19 pneumonia, but it didn't work since it was ineffective and didn't improve illness outcomes.